Global InformationTalazoparib information
 | |
| Clinical data | |
|---|---|
| Trade names | Talzenna |
| Other names | BMN-673 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a618070 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth |
| Drug class | PARP inhibitor |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | 74% |
| Metabolism | Minimal metabolisation (<30%) |
| Elimination half-life | 90 (±58) hrs |
| Excretion | 69% in urine, 20% in feces |
| Identifiers | |
IUPAC name
| |
| CAS Number |
|
| DrugBank |
|
| ChemSpider |
|
| UNII |
|
| KEGG |
|
| ChEMBL |
|
| ECHA InfoCard | 100.249.319 |
| Chemical and physical data | |
| Formula | C19H14F2N6O |
| Molar mass | 380.359 g·mol−1 |
| 3D model (JSmol) |
|
SMILES
| |
InChI
| |
Talazoparib, sold under the brand name Talzenna, is an anti-cancer medication used for the treatment of breast cancer and prostate cancer.[5] It is an orally available poly ADP ribose polymerase PARP inhibitor marketed by Pfizer for the treatment of advanced breast cancer with germline BRCA mutations.[8] Talazoparib is similar to the first in class PARP inhibitor, olaparib.[9][10]
The most common adverse reactions of any grade were fatigue, anemia, nausea, neutropenia, headache, thrombocytopenia, vomiting, alopecia, diarrhea, decreased appetite.[11]
It was approved in October 2018, in the United States and June 2019, in the European Union for germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer.[9][12][13][7] In January 2024, the European Commission approved talazoparib in combination with enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adults.[14]
- ^ a b "Talzenna APMDS". Therapeutic Goods Administration (TGA). 26 May 2022. Retrieved 10 March 2024.
- ^ "Talzenna Product information". Health Canada. 25 April 2012. Archived from the original on 30 May 2022. Retrieved 29 May 2022.
- ^ "Summary Basis of Decision (SBD) for Talzenna". Health Canada. 23 October 2014. Archived from the original on 31 May 2022. Retrieved 29 May 2022.
- ^ "Talzenna 0.25 mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). 1 June 2021. Archived from the original on 9 July 2021. Retrieved 9 July 2021.
- ^ a b "Talzenna- talazoparib capsule". DailyMed. 4 September 2023. Archived from the original on 30 July 2023. Retrieved 13 November 2023.
- ^ "Talzenna- talazoparib capsule". DailyMed. 4 September 2023. Archived from the original on 29 May 2023. Retrieved 13 November 2023.
- ^ a b "Talzenna EPAR". European Medicines Agency (EMA). 8 July 2019. Archived from the original on 19 May 2020. Retrieved 10 March 2020.
- ^ Medivation Inc. "Talazoparib". Archived from the original on 8 June 2017. Retrieved 21 November 2016.
- ^ a b "FDA approves Lynparza to treat advanced ovarian cancer". U.S. Food and Drug Administration (FDA) (Press release). 19 December 2014. Archived from the original on 19 December 2014. Retrieved 16 December 2019.
- ^ Brown JS, Kaye SB, Yap TA (March 2016). "PARP inhibitors: the race is on". British Journal of Cancer. 114 (7): 713–5. doi:10.1038/bjc.2016.67. PMC 4984871. PMID 27022824.
- ^ Cite error: The named reference
FDA 20181016was invoked but never defined (see the help page). - ^ "European Commission Approves Talzenna (talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer" (Press release). Pfizer Inc. Archived from the original on 22 September 2020. Retrieved 23 June 2019.
- ^ "Drug Approval Package: Talzenna (talazoparib)". U.S. Food and Drug Administration (FDA). 29 October 2018. Archived from the original on 30 October 2020. Retrieved 10 March 2020.
- ^ "Pfizer's Talzenna combination receives EC approval for metastatic prostate cancer". PMLive. 10 January 2024. Retrieved 11 January 2024.